RxDoctor Payments Data

Aaron Notestine, MD

Cardiovascular Disease · Coeur D Alene, IDNPI 1194831057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boston Scientific at 30.5% of the total. Reporting peaked in 2019 at $51 and has fallen 66.8% since, to $17 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in ID, where the typical reported total is $1,233.

$141in general payments, 2019–2025

Across 8 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$43
  • Johnson & Johnson$19
  • Shockwave Medical, Inc$19
  • AstraZeneca$18
  • E.r. Squibb & Sons, L.L.C.$17
  • Chiesi USA, Inc.$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$141100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$141 in reported general payments places this provider in the 15th percentile of 59 cardiovascular disease providers in Idaho.

See all cardiovascular disease providers in Idaho

Medicare billing

Part B allowed, 2024
$177,833
Medicare patients
1,546
Services billed
3,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban509$667,471
Repatha SureclickEvolocumab116$166,184
EntrestoSacubitril/Valsartan88$144,146
XareltoRivaroxaban109$135,164
Praluent PenAlirocumab74$88,396
JardianceEmpagliflozin23$32,390
Atorvastatin Calcium650$8,243
Metoprolol Succinate414$7,917
Potassium Chloride142$4,400
Rosuvastatin Calcium271$3,451
Ranolazine ErRanolazine26$3,316
Amlodipine Besylate291$2,300
Carvedilol318$2,291
Losartan Potassium199$1,793
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$1,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$135,164109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 59 cardiovascular disease providers in Idaho.

Other cardiovascular disease in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →